Literature DB >> 34222743

Alcohol-Associated Liver Disease Before and After COVID-19-An Overview and Call for Ongoing Investigation.

Andrew M Moon1, Brenda Curtis2, Pranoti Mandrekar3, Ashwani K Singal4,5, Elizabeth C Verna6, Oren K Fix1.   

Abstract

The Coronavirus Disease 2019 (COVID-19) pandemic has exacted a heavy toll on patients with alcohol-associated liver disease (ALD) and alcohol use disorder (AUD). The collective burden of ALD and AUD was large and growing, even before the COVID-19 pandemic. There is accumulating evidence that this pandemic has had a large direct effect on these patients and is likely to produce indirect effects through delays in care, psychological strain, and increased alcohol use. Now a year into the pandemic, it is important that clinicians fully understand the effects of the COVID-19 pandemic on patients with ALD and AUD. To fill existing gaps in knowledge, the scientific community must set research priorities for patients with ALD regarding their risk of COVID-19, prevention/treatment of COVID-19, changes in alcohol use during the pandemic, best use of AUD treatments in the COVID-19 era, and downstream effects of this pandemic on ALD.
Conclusion: The COVID-19 pandemic has already inflicted disproportionate harms on patients with ALD, and ongoing, focused research efforts will be critical to better understand the direct and collateral effects of this pandemic on ALD.
© 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.

Year:  2021        PMID: 34222743      PMCID: PMC8239751          DOI: 10.1002/hep4.1747

Source DB:  PubMed          Journal:  Hepatol Commun        ISSN: 2471-254X


  40 in total

1.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

2.  Alcohol Rehabilitation Within 30 Days of Hospital Discharge Is Associated With Reduced Readmission, Relapse, and Death in Patients With Alcoholic Hepatitis.

Authors:  Thoetchai Bee Peeraphatdit; Patrick S Kamath; Victor M Karpyak; Brian Davis; Vivek Desai; Suthat Liangpunsakul; Arun Sanyal; Naga Chalasani; Vijay H Shah; Douglas A Simonetto
Journal:  Clin Gastroenterol Hepatol       Date:  2019-04-28       Impact factor: 11.382

3.  Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV Alcohol Use Disorder in the United States, 2001-2002 to 2012-2013: Results From the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Bridget F Grant; S Patricia Chou; Tulshi D Saha; Roger P Pickering; Bradley T Kerridge; W June Ruan; Boji Huang; Jeesun Jung; Haitao Zhang; Amy Fan; Deborah S Hasin
Journal:  JAMA Psychiatry       Date:  2017-09-01       Impact factor: 21.596

4.  Tobacco use following liver transplantation for alcoholic liver disease: an underestimated problem.

Authors:  Andrea DiMartini; Lubna Javed; Sarah Russell; Mary Amanda Dew; Mary Grace Fitzgerald; Ashok Jain; John Fung
Journal:  Liver Transpl       Date:  2005-06       Impact factor: 5.799

5.  Alcoholic Liver Disease Replaces Hepatitis C Virus Infection as the Leading Indication for Liver Transplantation in the United States.

Authors:  George Cholankeril; Aijaz Ahmed
Journal:  Clin Gastroenterol Hepatol       Date:  2017-12-01       Impact factor: 11.382

6.  National Trends and Long-term Outcomes of Liver Transplant for Alcohol-Associated Liver Disease in the United States.

Authors:  Brian P Lee; Eric Vittinghoff; Jennifer L Dodge; Giuseppe Cullaro; Norah A Terrault
Journal:  JAMA Intern Med       Date:  2019-03-01       Impact factor: 21.873

Review 7.  Alcohol's Effect on Host Defense.

Authors:  Gyongyi Szabo; Banishree Saha
Journal:  Alcohol Res       Date:  2015

8.  Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.

Authors:  Thomas Marjot; Andrew M Moon; Jonathan A Cook; Sherief Abd-Elsalam; Costica Aloman; Matthew J Armstrong; Elisa Pose; Erica J Brenner; Tamsin Cargill; Maria-Andreea Catana; Renumathy Dhanasekaran; Ahad Eshraghian; Ignacio García-Juárez; Upkar S Gill; Patricia D Jones; James Kennedy; Aileen Marshall; Charmaine Matthews; George Mells; Carolyn Mercer; Ponni V Perumalswami; Emma Avitabile; Xialong Qi; Feng Su; Nneka N Ufere; Yu Jun Wong; Ming-Hua Zheng; Eleanor Barnes; Alfred S Barritt; Gwilym J Webb
Journal:  J Hepatol       Date:  2020-10-06       Impact factor: 25.083

Review 9.  COVID-19 and liver disease: mechanistic and clinical perspectives.

Authors:  Thomas Marjot; Gwilym J Webb; Alfred S Barritt; Andrew M Moon; Zania Stamataki; Vincent W Wong; Eleanor Barnes
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-03-10       Impact factor: 73.082

10.  Cirrhosis and Severe Acute Respiratory Syndrome Coronavirus 2 Infection in US Veterans: Risk of Infection, Hospitalization, Ventilation, and Mortality.

Authors:  George N Ioannou; Peter S Liang; Emily Locke; Pamela Green; Kristin Berry; Ann M O'Hare; Javeed A Shah; Kristina Crothers; McKenna C Eastment; Vincent S Fan; Jason A Dominitz
Journal:  Hepatology       Date:  2021-06-02       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.